News
CELC
126.07
+4.98%
5.98
Weekly Report: what happened at CELC last week (0413-0417)?
Weekly Report · 1d ago
Weekly Report: what happened at CELC last week (0406-0410)?
Weekly Report · 04/13 09:05
Weekly Report: what happened at CELC last week (0330-0403)?
Weekly Report · 04/06 09:05
Celcuity director Richard E. Buller disposes CELC shares worth 0.3 million
Reuters · 04/02 20:07
Weekly Report: what happened at CELC last week (0323-0327)?
Weekly Report · 03/30 09:05
H.C. Wainwright Sticks to Their Hold Rating for Celcuity (CELC)
TipRanks · 03/27 10:57
Celcuity’s Earnings Call: Big Data, Bigger Ambitions
TipRanks · 03/27 00:26
Celcuity Buy Rating Backed by Strong Gedatolisib Data, Upcoming VIKTORIA-1 Catalyst, and Favorable Risk-Reward
TipRanks · 03/26 17:35
Celcuity Is Maintained at Buy by Stifel
Dow Jones · 03/26 15:08
Stifel Maintains Buy on Celcuity, Raises Price Target to $125
Benzinga · 03/26 14:58
Celcuity price target raised to $141 from $108 at Craig-Hallum
TipRanks · 03/26 14:50
Celcuity Price Target Maintained With a $122.00/Share by Needham
Dow Jones · 03/26 12:30
Needham Reiterates Buy on Celcuity, Maintains $122 Price Target
Benzinga · 03/26 12:19
Celcuity Posts Wider FY25 Loss, Highlights Progress Toward Potential Gedatolisib Launch
NASDAQ · 03/26 11:10
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Maze Therapeutics, Inc. (MAZE)
TipRanks · 03/26 11:01
Celcuity: Clinical Momentum, Strong Balance Sheet, and Regulatory Catalysts Underpin Buy Rating and $122 Target
TipRanks · 03/26 10:45
Celcuity price target raised to $125 from $115 at Stifel
TipRanks · 03/26 10:35
CELCUITY INC <CELC.O>: STIFEL RAISES TARGET PRICE TO $125 FROM $115
Reuters · 03/26 10:34
Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations
Seeking Alpha · 03/26 00:16
Celcuity (Giredestrant): Anticipated PIK3CA Data and Global Regulatory Momentum Support Buy Rating
TipRanks · 03/25 23:05
More
Webull provides a variety of real-time CELC stock news. You can receive the latest news about Celcuity Inc through multiple platforms. This information may help you make smarter investment decisions.
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.